Full Text View
Tabular View
No Study Results Posted
Related Studies
Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa
This study has been completed.
Study NCT01113281   Information provided by Vakzine Projekt Management GmbH

First Received on April 27, 2010.   Last Updated on November 18, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Tuberculosis
More general conditions related to this trial
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections
Interventions listed in this trial
VPM1002 live vaccine
Additional drug interventions recognized in this trial
BCG Vaccine
More general drug interventions related to this trial
Adjuvants, Immunologic
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Vakzine Projekt Management GmbH
Farmovs-Parexel Bloemfontein, Republic of South Africa (Clinical Site)
Triclinium Johannesburg, RSA (Monitoring and Overall Management of the study)
Stellenbosch University Capetown, RSA (Immunogenicity Lab)
HJ-CTC George, RSA (Statistics & Report)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services